Nusinersen (Spinraza)
Antisense oligonucleotide therapy for spinal muscular atrophy via SMN2 splicing modification.
What is Nusinersen?
What it targets
SMN2 pre-mRNA splicing: nusinersen promotes exon 7 inclusion, producing more full-length functional SMN protein needed for motor neuron survival.
Who it may help
Patients with genetically confirmed 5q SMA — from symptomatic infants to adults — where intrathecal treatment can be safely administered.
Why testing matters
SMN1 gene testing confirms SMA diagnosis; SMN2 copy number informs prognosis and planning. Both guide treatment decisions and monitoring.
Which conditions can Nusinersen treat?
Nusinersen is approved for spinal muscular atrophy across a range of ages and SMA presentations — from symptomatic infants to adults.
| 5q SMA — Infantile-Onset (SMA Type 1) | The primary approved indication in most regions. In the ENDEAR randomised trial, significantly more treated infants achieved motor milestones and showed motor function improvement compared with untreated infants. Early treatment before severe motor neuron loss gives the best outcomes. |
| Later-Onset SMA (Types 2 and 3) | Approved for use in symptomatic children, adolescents, and adults with later-onset SMA. The CHERISH trial demonstrated significantly improved motor function scores compared with untreated patients, who typically declined over the same period. |
| Presymptomatic SMA | Patients identified through newborn screening before symptoms appear may be treated very early. The NURTURE study showed that most treated presymptomatic infants achieved developmental milestones including sitting independently and walking — outcomes markedly better than the natural disease course. |
Are you eligible for Nusinersen?
Eligibility depends on confirmed SMA diagnosis, ability to safely undergo intrathecal injection, organ function, and assessment by an experienced specialist.
- Genetically confirmed 5q SMA — SMN1 gene deletion or mutation confirmed by testing
- Diagnosis and prescription by a neurologist or specialist experienced in SMA management
- Ability to safely undergo lumbar puncture or image-guided intrathecal injection
- Adequate platelet count and coagulation function assessed before each dose
- No active fever or infection at the lumbar puncture site at the time of injection
- Urine protein monitoring: kidney function assessed before each dose is administered
- Respiratory and swallowing status reviewed to confirm patient stability for the procedure
- Pregnancy: specialist consultation required — benefit and risk must be discussed before starting
How does Nusinersen work?
- The SMN protein problem in SMA
- The SMN2 backup gene
- How Nusinersen modifies SMN2 splicing
- Why it must be given intrathecally
- Effect on motor neuron function and clinical outcomes
Nusinersen was the first approved medicine shown to modify the course of SMA — a disease with no approved treatment before December 2016.
Tests required before and during Nusinersen treatment
These tests confirm SMA diagnosis, assess procedure safety, and monitor for treatment-related effects throughout the course of therapy.
| SMN1 Gene Testing | Confirms SMA diagnosis by identifying SMN1 gene deletion or mutation. This is the essential prerequisite for Nusinersen prescribing and must be completed before treatment starts. |
| SMN2 Copy Number Testing | Provides prognostic information about expected disease severity. Higher copy numbers typically correlate with milder disease. Guides counselling and long-term treatment planning. |
| Platelet Count (CBC) | Assessed before each dose. Thrombocytopenia (low platelet count) increases bleeding risk during the lumbar puncture procedure and may require treatment postponement. |
| Coagulation Tests (PT/aPTT) | Checked before each injection to screen for coagulation abnormalities that could increase procedural bleeding risk. Abnormal results may require specialist input before proceeding. |
| Urine Protein Testing | Checked before each dose. Antisense oligonucleotides of this class have been associated with kidney-related protein changes. Persistent proteinuria requires specialist assessment. |
| Spine Imaging Assessment | Reviewed if severe scoliosis, spinal rods, or prior spinal surgery is present — these may require image-guided (ultrasound, fluoroscopy, or CT) injection by an experienced specialist. |
| Respiratory Assessment | Pulmonary function review or clinical respiratory assessment is important, especially in infants and patients with advanced weakness who may need ventilatory support during the procedure. |
| Baseline Motor Function Assessment | Age-appropriate SMA scales (CHOP-INTEND for infants, HFMSE for older patients) establish a baseline that is compared at follow-up visits to objectively track treatment response. |
How is Nusinersen given?
Nusinersen is given as an intrathecal injection directly into the cerebrospinal fluid. It is not a tablet or IV infusion — it requires a lumbar puncture procedure performed by a trained specialist at a hospital or specialist centre.
| Standard dose | 12 mg per intrathecal injection, administered by a trained healthcare professional experienced in lumbar puncture or intrathecal injection procedures. |
| High-dose regimen (FDA approved March 2026) | 28 mg per injection — an alternative higher-dose regimen approved by the FDA in March 2026. Discuss with your specialist whether this option is available at your centre and whether it applies to your situation. |
| Loading doses | Four loading doses are given on Days 1, 15, 29, and 64. These doses build drug levels in the cerebrospinal fluid quickly. All four loading doses should be completed on schedule. |
| Maintenance dosing | After the four loading doses, a maintenance dose is given approximately every 4 months for the long term. Treatment is ongoing — maintenance doses should not be missed or significantly delayed. |
| Procedure support and guidance | Sedation, general anesthesia, ultrasound, fluoroscopy, or CT guidance may be needed depending on patient age, weight, anatomy, or degree of cooperation. The treating team will plan this in advance. |
| Missed or rescheduled dose | Contact the treating specialist promptly if a dose needs rescheduling. Do not skip doses or delay without medical guidance. Gaps in treatment may reduce effectiveness. |
| Duration | Nusinersen is a long-term therapy. Treatment continues as long as clinical benefit is maintained and the specialist assesses it appropriate for the individual patient. |
Clinical evidence and benefits
Nusinersen was evaluated in randomised controlled trials in both infantile-onset and later-onset SMA, with long-term extension data available from the SHINE study.
| Motor milestone improvement — ENDEAR trial (infantile SMA) | Significantly more infants treated with Nusinersen achieved motor milestones — such as head control, ability to roll, and supported sitting — compared with untreated infants. Untreated infants in the same trial showed progressive decline. |
| Later-onset SMA benefit — CHERISH trial | Children with later-onset SMA who received Nusinersen showed significantly better motor function scores on the HFMSE scale compared with untreated children. Untreated children typically declined over the same study period. |
| Presymptomatic advantage — NURTURE study | When treatment was started in presymptomatic infants identified through newborn screening, the majority achieved sitting independently and many achieved independent walking — outcomes substantially better than what is typically seen in the natural disease history of SMA. |
| Disease stabilisation as a meaningful goal | Some patients stabilise rather than show visible improvement. In a naturally progressive neuromuscular disease, maintaining current function over months to years represents a clinically significant outcome and is an accepted treatment goal. |
| Long-term durability — SHINE extension study | Long-term follow-up from the SHINE open-label extension supports maintained benefit in patients who continue treatment. Data continue to be collected to understand the very long-term outcomes of lifelong therapy. |
Individual responses vary widely. Age at treatment start, SMA type, baseline motor function, SMN2 copy number, and quality of supportive care all influence outcomes. These represent clinical trial findings, not guaranteed individual results.
Side effects of Nusinersen
Nusinersen side effects include both procedure-related effects from the lumbar puncture and effects associated with the medicine itself. Most patients tolerate treatment, but safety monitoring before and after each dose is important.
| Headache | Common after lumbar puncture — often a positional post-procedure headache. Usually resolves within a few days with rest, lying flat, and adequate hydration. Report severe or worsening headache promptly. |
| Back pain | Related to the injection procedure site. Usually mild and temporary. Report back pain that is worsening, spreading, or not improving to the medical team. |
| Vomiting | Can occur around the time of the procedure, particularly in young children and patients under sedation. Usually manageable with supportive care. |
| Fever (pyrexia) | Reported in clinical trials. Monitor for signs of underlying infection if fever develops after a procedure. Contact the team if fever is persistent or associated with other new symptoms. |
| Constipation | Reported in clinical trials. Adequate hydration and dietary adjustments may help. Discuss with the care team if persistent. |
| Lower respiratory infection | Patients with SMA-related breathing weakness are at higher baseline risk of respiratory infections. This reflects the underlying disease as much as the drug. Respiratory assessment and infection prevention are part of comprehensive SMA care. |
| Post-lumbar puncture syndrome | A syndrome of positional headache, nausea, neck stiffness, and sensitivity to light or sound after the injection. Usually improves with lying flat, rest, and fluids. Severe or prolonged cases should be assessed by the care team. |
| Thrombocytopenia (low platelet count) | Antisense oligonucleotides of this class can reduce platelet counts. Platelet levels are checked before each dose. If counts are low, treatment may be postponed until they recover to safe levels for the lumbar puncture. |
| Coagulation abnormalities | Changes in clotting test results have been reported. Coagulation is assessed before each dose to reduce procedural bleeding risk. Abnormal results require specialist input before proceeding. |
| Proteinuria (elevated urine protein) | Protein in the urine is monitored before doses because this drug class has been associated with kidney-related changes. Persistent or worsening proteinuria requires further assessment and may affect dosing. |
Contact your doctor urgently if you develop:
- Breathing difficulty, rapid breathing, or worsening respiratory status after injection
- Severe or worsening headache, stiff neck, high fever, or signs of meningitis after injection
- Unusual or unexpected bleeding, unexplained bruising, or blood in urine after treatment
- Worsening weakness, loss of previously achieved motor function, or sudden neurological change
- High fever or severe back pain that does not improve after the injection procedure
Safety precautions and important warnings
Tell the treating specialist and pharmacist about all medical conditions, medicines, supplements, and recent vaccinations before every dose of Nusinersen.
- Active infection or fever: treatment should be postponed until infection resolves to reduce procedure and safety risk
- Bleeding disorders or anticoagulant use: platelet count and coagulation must be checked before each injection
- Kidney disease or abnormal urine protein: close monitoring required; dose delay or specialist review may be needed
- Severe scoliosis, spinal rods, or prior spinal surgery: image-guided specialist injection may be necessary for safe access
- Pregnancy: consult specialist before starting — discuss potential fetal risks with an experienced physician
- Breastfeeding: discuss risks and benefits with the treating team; data in breastfeeding is limited
- Live vaccines: discuss vaccination timing with the SMA team before any live vaccine is given
- All medicines and herbal supplements should be disclosed — drug interactions with antisense oligonucleotides may not be fully characterised
Nusinersen with other SMA treatments and supportive care
SMA management involves more than disease-modifying therapy alone. Comprehensive supportive care is essential alongside Nusinersen.
| Respiratory support | Non-invasive ventilation, mechanical ventilation, cough assist devices, and regular respiratory monitoring are used alongside Nusinersen, particularly in patients with respiratory muscle weakness. |
| Nutrition and feeding support | Gastrostomy feeding or dedicated nutritional support may be needed for patients with swallowing difficulty or inadequate weight gain. Nutrition management is a core component of SMA care alongside drug therapy. |
| Physiotherapy, rehabilitation, and orthopedic care | Regular physiotherapy, orthopedic management including scoliosis care, and rehabilitation are essential alongside disease-modifying therapy to maintain and maximise motor function. |
| Switching or sequencing with other SMA therapies | Some patients may have received Zolgensma (gene therapy) or may consider transitioning to Evrysdi (risdiplam, oral daily medicine). Switching or sequencing SMA therapies is complex and must be guided by an SMA specialist. |
| Nusinersen after gene therapy | Real-world data on sequential use of Zolgensma followed by Nusinersen is limited. This decision requires careful specialist review of prior treatment history, current clinical status, and expected benefit versus risk. |
If Nusinersen does not work as expected
Some patients may not respond as hoped or may plateau over time. Understanding the reasons guides next steps and treatment decisions.
| Late treatment start | Starting after severe irreversible motor neuron loss has already occurred limits what any SMA therapy can achieve. This is why early diagnosis — particularly through newborn screening — significantly improves outcomes. |
| Disease progression despite treatment | If motor function continues to decline, the specialist will reassess respiratory, nutritional, orthopedic, and rehabilitation support needs, review dose adherence and procedure timing, and consider whether an alternative SMA therapy is appropriate. |
| Alternative SMA disease-modifying therapies | Risdiplam (Evrysdi), an oral once-daily SMN2 splicing modifier, may be considered as an alternative for patients who cannot continue intrathecal therapy or who are not achieving adequate benefit. Onasemnogene abeparvovec (Zolgensma) is typically an option for younger or lighter patients and is a one-time treatment. |
| Specialist second opinion and centre review | If expected response is not achieved, CancerFax can help connect patients with specialist neuromuscular centres experienced in SMA for an independent assessment and review of treatment options. |
Cost of Nusinersen by country
Nusinersen is one of the most expensive medicines in the world because of its rare disease status, requirement for repeated specialist-administered doses, and complex monitoring schedule.
| India | Nusinersen is not locally approved in India as of mid-2026. Named-patient import may be possible but involves regulatory steps and very high costs including drug price, procedure costs, and ongoing monitoring. Families should seek formal written estimates. CancerFax can help explore access options. |
| USA | The listed price of Spinraza in the USA has been reported as several hundred thousand dollars in the first year and over USD 350,000 for each subsequent year. Most patients access it through insurance, Medicaid, or Biogen's patient support programs. No approved generic is currently available in the USA. |
| UK / Europe | Spinraza is EMA-authorised. Access in the UK (NHS), Germany, France, Italy, and other European countries varies significantly based on national health technology assessment decisions and managed entry agreements. Some countries have access restrictions based on SMA type, age, or motor function. |
| China | Nusinersen was approved by China's NMPA in 2019 and was subsequently added to China's National Reimbursement Drug List (NRDL), significantly reducing patient cost burden under national health insurance. Access is available at approved SMA specialist centres in China. |
| Japan and other countries | Japan approved nusinersen for SMA and it is covered under national health insurance. In Southeast Asia, the Middle East, and other regions, availability varies by country. Specialist import or named-patient pathways may apply where local approval is absent. |
Availability of Nusinersen globally
Nusinersen is available in many high-income countries through national health systems. Access in developing countries depends on local approval, specialist infrastructure, and reimbursement policies.
USA
FDA approved since December 2016. Available at major neuromuscular and academic medical centres. Covered by most insurance plans and Medicaid. Biogen patient support programs available for eligible patients with limited coverage.
Europe
EMA authorised. Available across most EU countries and the UK. Reimbursement conditions and access restrictions vary significantly by country — some require specific SMA type, age group, or motor function criteria for public funding.
China
NMPA approved in 2019. Included on the National Reimbursement Drug List (NRDL), making treatment significantly more affordable under China's national health insurance at approved SMA specialist centres.
India
Not locally approved as of mid-2026. Access may be explored via named-patient import pathway requiring specialist centre evaluation, regulatory assessment, and significant financial planning. Verify current status before proceeding.
Japan
Approved for SMA in Japan. Available at designated neuromuscular disease and paediatric neurology centres. Covered under national health insurance for eligible patients following specialist diagnosis and prescription.
Nusinersen in ongoing clinical research
Research continues to explore higher dosing regimens, long-term outcomes, earlier treatment in newborn-screened patients, adult SMA, and optimal sequencing with other SMA therapies.
| High-dose regimen studies | Following FDA approval of a 28 mg higher-dose regimen in March 2026, research is evaluating whether higher doses produce faster or better clinical benefit across SMA types and age groups. |
| Presymptomatic and newborn-screened SMA | Studies in presymptomatic infants identified through national newborn screening programs continue to assess very early treatment outcomes and long-term developmental trajectories over years of follow-up. |
| Adult SMA populations | Adult patients with SMA have historically been underrepresented in SMA trials. Ongoing studies evaluate the benefit, tolerability, and optimal dosing strategies in adult SMA populations. |
| Sequencing and switching SMA therapies | Research examines how to best sequence or switch between Nusinersen, risdiplam, and gene therapy — including safety data and efficacy outcomes when patients transition from one mechanism to another. |
| Biomarker and outcome research | Studies are validating blood and CSF biomarkers — including neurofilament light chain (NfL) — that may predict treatment response and guide long-term monitoring and therapy decisions. |
Your treatment journey with Nusinersen
Symptom recognition and specialist referral
Genetic confirmation of SMA
Specialist evaluation and treatment planning
First intrathecal injection — loading phase
Completing the four loading doses
Transition to maintenance therapy
Long-term monitoring and comprehensive SMA care
Questions to ask your doctor about Nusinersen
- Has SMA been genetically confirmed, and what does the SMN2 copy number mean?
- Is Nusinersen the right SMA therapy for my child or for me?
- What is the dosing schedule and how many hospital visits will be needed?
- What tests are needed before each injection?
- What side effects should I watch for at home after each injection?
- What is the realistic goal — motor improvement or disease stabilisation?
- Is the higher-dose Nusinersen regimen available at our centre?
- What is the expected long-term cost and how can we plan for continued access?
How CancerFax supports Nusinersen patients
CancerFax supports patients and families navigating SMA treatment decisions, access challenges, specialist connections, and international care coordination.
| Report review | Upload your genetic test results, motor function reports, and specialist letters — our team will review them and help you understand what they mean for Nusinersen eligibility and treatment planning. |
| Specialist connection | We connect patients with neurologists, pediatric neurologists, and SMA specialists in India, China, and international centres who have experience with Nusinersen and comprehensive SMA care programs. |
| Access and import guidance | For patients in India and other countries where Nusinersen is not locally approved, CancerFax can help explore named-patient import pathways, specialist centre options, and practical access steps. |
| China SMA treatment access | Nusinersen is approved and reimbursed under China's national health insurance at specialist SMA centres. CancerFax can help families understand what seeking treatment in China practically involves. |
| Second opinion for SMA therapy selection | If you are uncertain whether to choose Nusinersen, risdiplam, gene therapy, or another approach, CancerFax can arrange a specialist second opinion to help clarify which path is right for your patient. |
| Cost and reimbursement navigation | CancerFax helps families understand cost estimates, insurance processes, government schemes, and patient assistance pathways relevant to Nusinersen in their country of residence or treatment. |
Frequently asked questions about Nusinersen
Common questions from SMA patients, families, and caregivers
Nusinersen (Spinraza) is an antisense oligonucleotide medicine for spinal muscular atrophy. It binds to a specific site on SMN2 pre-mRNA and modifies how the gene is spliced, so the body produces more full-length, functional SMN protein. More SMN protein supports the survival and function of motor neurons in the spinal cord, which are damaged in SMA.
Nusinersen is a disease-modifying therapy, not a cure. It does not repair or replace the faulty SMN1 gene but uses the backup SMN2 gene to produce more functional protein. In clinical trials, many patients showed improved or stabilised motor function compared with untreated patients. Treatment must continue long-term and outcomes vary between individuals.
Treatment begins with four loading doses given approximately on Days 1, 15, 29, and 64, followed by a maintenance dose approximately every 4 months indefinitely. The standard dose is 12 mg per injection. In March 2026, the FDA approved an additional higher-dose regimen — discuss with your specialist whether this applies. Each dose requires a hospital visit for an intrathecal injection procedure.
All three target SMN protein production but work differently. Nusinersen is an antisense oligonucleotide given by intrathecal injection every 4 months. Zolgensma (onasemnogene abeparvovec) is a one-time gene therapy given by IV infusion, typically for younger or lighter patients. Evrysdi (risdiplam) is a daily oral medicine that also modifies SMN2 splicing and can be given at home. The right choice depends on age, SMA type, access, and specialist judgment.
Nusinersen does not have local regulatory approval in India as of mid-2026. Access may be explored via named-patient import, but this involves significant regulatory steps, specialist centre requirements, and high cost. CancerFax can help families in India explore access options — including whether treatment at approved specialist centres in China, where Nusinersen is on the national reimbursement list, may be a practical alternative.
Nusinersen is among the most expensive medicines in the world. In the USA, annual costs have been reported in the hundreds of thousands of dollars. In China, it was added to the National Reimbursement Drug List, making it significantly more accessible under national insurance. In other countries, cost depends on insurance coverage, government reimbursement, and patient assistance programs. Families should request written cost estimates and ask about all available support pathways.
Yes — Nusinersen is FDA-approved for both pediatric and adult patients with SMA. Clinical evidence is strongest in patients treated early, but adults with SMA may still benefit. The specialist will assess potential benefit against the procedural requirements, monitoring burden, and individual clinical status before recommending treatment for an adult patient.
If expected motor benefit is not achieved or function declines, the SMA specialist will review the diagnosis, dose adherence, respiratory and nutritional status, and whether another SMA therapy — such as risdiplam — might be appropriate. Some patients stabilise rather than show visible improvement, which can still be a meaningful clinical outcome in a progressive disease. CancerFax can help arrange a specialist second opinion if needed.